How exactly the ReHeal Glove got to where it is now—flush with funding and undergoing various rounds of testing—is largely due to the role of the Medical Technology Enterprise Consortium (MTEC), a nonprofit corporation that operates as the premier facilitator and collaborator across the entire DOD. Indeed, if it weren’t for MTEC, the near decade-long effort to develop the ReHeal Glove may have withered on the vine. Instead, it provides a promising medical option for millions.
Apheresis services firm Terumo Blood and Cell Technologies has entered into a contract with the Medical Technology Enterprise Consortium (MTEC), which is an Other Transaction Agreement (OTA) with the US Army Medical Research and Development Command.
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio therapeutic solutions for tissue repair and regeneration, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded MediWound a $1.7 million research project for the development of NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army (the "MTEC Research Project Award").
The goal is to help the DoD better execute its National Defense Strategy by preventing various forms of violent, abusive and harmful acts within military contexts.
Across the country, the organizations are relieving stressed-out critical-care teams and filling in where necessary to fight COVID-19. The telehealth system is ready for other disasters, as well.
“We need to place cutting-edge technology quickly into the hands of the warfighter,” said Sara Langdon, USAMRDC’s program manager for other-transaction authority with the Medical Technology Enterprise Consortium (MTEC). “It is vital that we partner in order to fill our medical capability gaps, and OTAs help us to accomplish this.”
Imbed Biosciences, Inc. (Imbed) announced today that it has been awarded a contract for $1,999,481 by the U.S. Army Medical Research and Development Command's (USAMRDC) Military Infectious Diseases Research Program (MIDRP) to accelerate clinical development of an antibiofilm version of its next-generation Microlyte® Matrix wound dressing that can kill bacteria hidden in biofilms. The contract was awarded through Medical Technology Enterprise Consortium (MTEC) for prototype solutions that prevent combat wound infections following blast injuries and burns.
This project, titled “Augmented Neurophysiology of Sleep and Performance Readiness,” is part of the Medical Technology Enterprise Consortium, a collaboration between industry and academia to facilitate research and development activities, in cooperation with the U.S. Army Medical Research and Development Command and other Department of Defense agencies in the biomedical sciences to protect, treat, and optimize the health and performance of military personnel.
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced new development funding from the US Army for its Covid-19 monoclonal antibody drug cocktail. The support is provided by the US Army Medical Research and Development Command (USAMRDC), operating through the Medical Technology Enterprise Consortium (MTEC).
Researchers at the University of Alabama at Birmingham will investigate the usefulness of a new non-invasive method to measure the expansion of hematomas in the brain. This project is funded by the Combat Casualty Care Research Program’s Neurotrauma Program at the US Army Medical Research and Development Command via the Medical Technology Enterprise Consortium.
